[go: up one dir, main page]

WO2010060102A3 - Prediction and prevention of preeclampsia - Google Patents

Prediction and prevention of preeclampsia Download PDF

Info

Publication number
WO2010060102A3
WO2010060102A3 PCT/US2009/065795 US2009065795W WO2010060102A3 WO 2010060102 A3 WO2010060102 A3 WO 2010060102A3 US 2009065795 W US2009065795 W US 2009065795W WO 2010060102 A3 WO2010060102 A3 WO 2010060102A3
Authority
WO
WIPO (PCT)
Prior art keywords
preeclampsia
pregnant woman
methods
relaxin
prediction
Prior art date
Application number
PCT/US2009/065795
Other languages
French (fr)
Other versions
WO2010060102A2 (en
Inventor
Dennis R. Stewart
Kirk P. Conrad
Arundhathi Jeyabalan
Original Assignee
Corthera, Inc.
University Of Pittsburgh-Of The Commonwealth System Of Higher Education
University Of Florida Research Foundation, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to RU2011125546/15A priority Critical patent/RU2538661C2/en
Priority to MX2011005454A priority patent/MX2011005454A/en
Priority to CA2742792A priority patent/CA2742792A1/en
Priority to CN200980146884.9A priority patent/CN102224420B/en
Priority to US13/129,597 priority patent/US8574851B2/en
Priority to JP2011537723A priority patent/JP5727938B2/en
Priority to BRPI0920897A priority patent/BRPI0920897A2/en
Application filed by Corthera, Inc., University Of Pittsburgh-Of The Commonwealth System Of Higher Education, University Of Florida Research Foundation, Inc. filed Critical Corthera, Inc.
Priority to EP09828391A priority patent/EP2368114A4/en
Priority to AU2009316278A priority patent/AU2009316278B2/en
Publication of WO2010060102A2 publication Critical patent/WO2010060102A2/en
Publication of WO2010060102A3 publication Critical patent/WO2010060102A3/en
Priority to US13/398,215 priority patent/US20130012441A1/en
Priority to US13/940,530 priority patent/US20130303455A1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)

Abstract

The present disclosure relates to methods for assessing increased risk of preeclampsia in a pregnant woman. The methods described herein employ measuring relaxin levels, and optionally measuring C-reactive protein levels in a biological sample of a pregnant woman. The disclosure further encompasses methods of reducing risk of preeclampsia through administration of a pharmaceutical formulation of relaxin to a pregnant woman.
PCT/US2009/065795 2008-11-24 2009-11-24 Prediction and prevention of preeclampsia WO2010060102A2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
EP09828391A EP2368114A4 (en) 2008-11-24 2009-11-24 PREDICTION AND PREVENTION OF ÉCLAMPSISME
CA2742792A CA2742792A1 (en) 2008-11-24 2009-11-24 Prediction and prevention of preeclampsia
CN200980146884.9A CN102224420B (en) 2008-11-24 2009-11-24 Prediction and prevention of preeclampsia
US13/129,597 US8574851B2 (en) 2008-11-24 2009-11-24 Prediction and prevention of preeclampsia
JP2011537723A JP5727938B2 (en) 2008-11-24 2009-11-24 How to test the high risk of developing pre-eclampsia
RU2011125546/15A RU2538661C2 (en) 2008-11-24 2009-11-24 Predicting and preventing preeclampsia
MX2011005454A MX2011005454A (en) 2008-11-24 2009-11-24 Prediction and prevention of preeclampsia.
BRPI0920897A BRPI0920897A2 (en) 2008-11-24 2009-11-24 prognosis and prevention of preeclampsia
AU2009316278A AU2009316278B2 (en) 2008-11-24 2009-11-24 Prediction and prevention of preeclampsia
US13/398,215 US20130012441A1 (en) 2008-11-24 2012-02-16 Prediction and prevention of preeclampsia
US13/940,530 US20130303455A1 (en) 2008-11-24 2013-07-12 Prediction and prevention of preeclampsia

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20015008P 2008-11-24 2008-11-24
US61/200,150 2008-11-24

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/398,215 Continuation-In-Part US20130012441A1 (en) 2008-11-24 2012-02-16 Prediction and prevention of preeclampsia

Publications (2)

Publication Number Publication Date
WO2010060102A2 WO2010060102A2 (en) 2010-05-27
WO2010060102A3 true WO2010060102A3 (en) 2011-01-06

Family

ID=42198859

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/065795 WO2010060102A2 (en) 2008-11-24 2009-11-24 Prediction and prevention of preeclampsia

Country Status (11)

Country Link
US (1) US8574851B2 (en)
EP (1) EP2368114A4 (en)
JP (2) JP5727938B2 (en)
KR (1) KR20110106316A (en)
CN (1) CN102224420B (en)
AU (1) AU2009316278B2 (en)
BR (1) BRPI0920897A2 (en)
CA (1) CA2742792A1 (en)
MX (1) MX2011005454A (en)
RU (1) RU2538661C2 (en)
WO (1) WO2010060102A2 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110251094A1 (en) * 2010-04-13 2011-10-13 Pronota N.V. Biomarkers for hypertensive disorders of pregnancy
BR112012028408B8 (en) 2010-05-08 2022-04-19 Bruin Biometrics Llc Scanner and device for detecting subepidermal moisture from a location external to the patient's skin
JP5899236B2 (en) * 2010-12-16 2016-04-06 コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． System and method for medical decision support for treatment planning using case-based reasoning
US9381231B2 (en) 2012-10-09 2016-07-05 University Of Florida Research Foundation, Inc. Use of relaxin to restore maternal physiology in pregnancies conceived by assisted reproductive technologies
US9907833B2 (en) 2013-07-25 2018-03-06 University Of Florida Research Foundation, Incorporated Use of relaxin to treat placental syndromes
FR3017955B1 (en) * 2014-02-27 2018-04-06 Assistance Publique - Hopitaux De Paris BIOMARKERS DIAGNOSTICS OF PERIPARTUM CARDIOMYOPATHY
RU2568892C1 (en) * 2014-08-28 2015-11-20 Федеральное государственное автономное образовательное учреждение высшего профессионального образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") Method of predicting severe pre-eclampsia
RU2568891C1 (en) * 2014-08-28 2015-11-20 Федеральное государственное автономное образовательное учреждение высшего профессионального образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") Method for prediction of risk of preeclampsia by combination of cytokine genes
RU2568893C1 (en) * 2014-09-04 2015-11-20 Федеральное государственное автономное образовательное учреждение высшего профессионального образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") Method of predicting development of pre-eclampsia in women with non-burdened heredity
CA2982249C (en) 2015-04-24 2019-12-31 Bruin Biometrics, Llc Apparatus and methods for determining damaged tissue using sub-epidermal moisture measurements
RU2636228C1 (en) * 2016-11-14 2017-11-21 Федеральное государственное бюджетное образовательное учреждение высшего образования "Алтайский государственный медицинский университет" Министерства здравоохранения Российской Федерации Method for preeclampsia prediction in pregnant women with mutation of factor v leiden 1691 gene of g/a and a/a genotype
RU2642939C1 (en) * 2016-12-08 2018-01-29 Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") Method for prediction of risk of preeclampsia
CN118177725A (en) 2017-02-03 2024-06-14 布鲁恩医疗创新有限责任公司 Measurement of susceptibility to diabetic foot ulcers
GB2596983B (en) 2017-02-03 2022-08-03 Bruin Biometrics Llc Measurement of edema
HUE065695T2 (en) 2017-02-03 2024-06-28 Bbi Medical Innovations Llc Measurement of tissue viability
NZ764101A (en) 2017-11-16 2025-05-30 Bruin Biometrics Llc Providing a continuity of care across multiple care settings
RU2682167C1 (en) * 2018-01-10 2019-03-15 Федеральное государственное бюджетное образовательное учреждение высшего образования "Пермский государственный медицинский университет имени академика Е.А. Вагнера" Министерства здравоохранения Российской Федерации Method for preeclampsia prevention
EP3749181B1 (en) 2018-02-09 2024-02-21 Bruin Biometrics, LLC Detection of tissue damage
RU2679111C1 (en) * 2018-08-06 2019-02-05 Федеральное государственное бюджетное образовательное учреждение высшего образования "Северо-Осетинская государственная медицинская академия" Министерства здравоохранения Российской Федерации Method for predicting the risk of development of pre-eclampsia in women of different somatotypes
SG10202111145XA (en) 2018-10-11 2021-11-29 Bruin Biometrics Llc Device with disposable element
RU2752776C1 (en) * 2020-12-16 2021-08-03 Федеральное государственное бюджетное образовательное учреждение высшего образования "Алтайский государственный медицинский университет" Министерства здравоохранения Российской Федерации Method for determining the duration of thromboprophylaxis with low-molecular-weight heparin after abdominal delivery in carriers of the leiden mutation, genotype f5 g1691a
MX2023009108A (en) 2021-02-03 2023-08-09 Bruin Biometrics Llc Methods of treating deep and early-stage pressure induced tissue damage.
WO2023041845A1 (en) * 2021-09-14 2023-03-23 Bellylabs Oy Assay method for relaxin
CN116953255A (en) * 2023-07-27 2023-10-27 山东大学 Use of total IgM and/or total IgG in serum in preeclampsia prediction or diagnosis

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080108572A1 (en) * 2004-04-30 2008-05-08 Bas Medical, Inc. Methods and compositions for control of fetal growth via modulation of relaxin

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5911997A (en) * 1995-06-07 1999-06-15 Connetics Corporation Relaxin-like factor and methods and uses thereof
US6723702B2 (en) 2000-02-09 2004-04-20 Ras Medical, Inc. Use of relaxin treat diseases related to vasoconstriction
US7338924B2 (en) 2002-05-02 2008-03-04 Exxonmobil Upstream Research Company Oil-in-water-in-oil emulsion
EP1482310A1 (en) * 2003-05-30 2004-12-01 Bayer HealthCare AG Relaxin as an independent risk factor predicting mortality
AU2005223694B2 (en) * 2004-03-19 2011-04-28 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Use of relaxin to increase arterial compliance
EP2216650A1 (en) * 2004-04-09 2010-08-11 University of Pittsburgh Real time method of detecting acute inflammatory conditions
JP5009811B2 (en) * 2004-12-21 2012-08-22 イェール ユニバーシティ Detection of preeclampsia
US20100113286A1 (en) * 2007-05-05 2010-05-06 Gilles Andre Lajoie Methods for detection of preeclampsia

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080108572A1 (en) * 2004-04-30 2008-05-08 Bas Medical, Inc. Methods and compositions for control of fetal growth via modulation of relaxin

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DECKER ET AL.: "Some effects of relaxin in obstetrics.", OBSTET GYNECOL, vol. 12, no. 1, 1958, pages 37 - 46 *
HWANG ET AL.: "Maternal serum highly sensitive C-reactive protein in normal pregnancy and pre- eclampsia.", INTERNATIONAL JOURNAL OF GYNECOLOGY AND OBSTETRICS, vol. 98, 2007, pages 105 - 109 *
NESS ET AL.: "Heterogeneous causes constituting the single syndrome of preeclamsia: a hypothesis and it's implications.", AM J OBSTET GYNECOL, vol. 175, 1996, pages 1365 - 70 *
QIU ET AL.: "A prospective study of matemal serum C-reactive protein concentrations and risk of preeclampsia.", AM J HYPERTENS, vol. 17, 2004, pages 154 - 160 *
SPENCER ET AL.: "First-trimester matemal serum PP-13, PAPP-A and second-trimester uterine artery Doppler pulsatility index as markers of pre-eclampsia.", ULTRASOUND OBSTET GYNECOL, vol. 29, 2007, pages 128 - 134 *

Also Published As

Publication number Publication date
RU2538661C2 (en) 2015-01-10
EP2368114A4 (en) 2012-06-13
JP5727938B2 (en) 2015-06-03
RU2011125546A (en) 2012-12-27
US8574851B2 (en) 2013-11-05
AU2009316278A1 (en) 2010-05-27
AU2009316278B2 (en) 2013-09-26
BRPI0920897A2 (en) 2015-12-29
CA2742792A1 (en) 2010-05-27
EP2368114A2 (en) 2011-09-28
KR20110106316A (en) 2011-09-28
CN102224420B (en) 2014-09-17
JP2012510061A (en) 2012-04-26
US20110281801A1 (en) 2011-11-17
CN102224420A (en) 2011-10-19
JP2015051989A (en) 2015-03-19
WO2010060102A2 (en) 2010-05-27
MX2011005454A (en) 2011-06-20

Similar Documents

Publication Publication Date Title
WO2010060102A3 (en) Prediction and prevention of preeclampsia
IT1406051B1 (en) USE OF HMGB1 AS A BIOLOGICAL MARKER OF HUMAN INTESTINAL INFLAMMATION, A NON-INVASIVE METHOD FOR ITS DETECTION IN FECAL SAMPLES AND RELATIVE KIT.
WO2011015944A3 (en) Use of free dna as an early predictor of severity in acute pancreatitis
WO2009090553A3 (en) Compositions and methods of detecting post-stop peptides
WO2007147076A3 (en) Methods for the diagnosis of fetal abnormalities
EP3955004A3 (en) Use of fatty acids in methods for detecting cancer
WO2011133668A3 (en) Methods and compositions for the treatment of cancer
EP2757365A3 (en) Capacitance detection in electrochemical assay with improved response
WO2014074835A3 (en) Antibody compositions and immunoassay methods to detect isoforms of anti-mullerian hormone
WO2006127861A3 (en) Diagnosis of diseases and conditions by analysis of histopathologically processed biological samples using liquid tissue preparations
WO2010135574A3 (en) Systems and methods for determining the percentage of glycated hemoglobin
WO2010005531A3 (en) Methods for the detection of advanced glycation endproducts and markers for disease
WO2012110878A3 (en) Method of diagnosing cancer and diagnosis kit using measurement of nk cell activity
CA2820841C (en) Competitive biosensor having elevated sensitivity
WO2011104517A3 (en) Capacitance detection in electrochemical assay
MX347871B (en) Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate.
WO2010090810A3 (en) Diagnostic device and method
EA201171178A1 (en) DEVICE AND METHOD FOR DETERMINATION AND QUANTITATIVE ANALYSIS OF ANALYSIS, IN PARTICULAR, MYCOTOXINS
WO2010033597A3 (en) Methods for detecting overexpression of sparc and therapeutic and diagnostic methods relating to same
WO2010031749A9 (en) Compositions and methods for detecting tlr3
EP2660310A4 (en) Comprehensive glaucoma determination method utilizing glaucoma diagnosis chip and deformed proteomics cluster analysis
PH12013500863A1 (en) Quantification and characterization of allergens
WO2011133036A3 (en) Means and methods for determining risk of cardiovascular disease
WO2012029224A8 (en) Method for detecting target substance, aptamer set used therefor, sensor, and device
MX2009001070A (en) Use of melanoma inhibitory activity (mia) protein as an early indicator for therapeutic response in melanoma.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980146884.9

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09828391

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2742792

Country of ref document: CA

Ref document number: 3325/DELNP/2011

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2009316278

Country of ref document: AU

REEP Request for entry into the european phase

Ref document number: 2009828391

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2009828391

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2011537723

Country of ref document: JP

Ref document number: MX/A/2011/005454

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2009316278

Country of ref document: AU

Date of ref document: 20091124

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20117014529

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2011125546

Country of ref document: RU

WWE Wipo information: entry into national phase

Ref document number: 13129597

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0920897

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20110524